How Are New GLP-1 Medications Different from Older Treatments for Obesity?

The Obesity Treatment Gap Before GLP-1 Receptor Agonists

Before semaglutide received FDA approval for chronic weight management in 2021, the anti-obesity medication toolkit was limited. Most drugs produced single-digit percentage weight loss and came with restrictions on duration of use, narrow mechanisms of action, or side-effect profiles that drove high discontinuation rates. The arrival of incretin-based therapies changed the clinical calculus entirely.

What Older Drugs Were Available

The FDA had approved five anti-obesity medications prior to semaglutide's weight management indication: phentermine (1959), orlistat (1999), phentermine-topiramate ER (Qsymia, 2012), naltrexone-bupropion ER (Contrave, 2014), and liraglutide 3.0 mg (Saxenda, 2014). Lorcaserin (Belviq) received approval in 2012 but was withdrawn in 2020 over cancer concerns.

Phentermine, a sympathomimetic amine, remains the most prescribed anti-obesity drug in the United States. It works by increasing norepinephrine release in the hypothalamus. The DEA classifies it as a Schedule IV controlled substance, and FDA labeling restricts its use to short-term therapy (a few weeks), though many clinicians prescribe it off-label for longer periods. Typical placebo-subtracted weight loss ranges from 3% to 6% of body weight.

Why Those Options Fell Short

Orlistat blocks pancreatic lipase in the gut, reducing dietary fat absorption by roughly 30%. In a Cochrane meta-analysis of 16 trials, orlistat produced only 2.9% placebo-subtracted weight loss at 12 months. Its oily stool and fecal urgency side effects led to poor adherence. Naltrexone-bupropion targets opioid and dopamine reward pathways, yielding 4.8 to 5.4% placebo-subtracted loss in the COR trial program, with nausea and headache as common barriers. None of these agents addressed the hormonal drivers of appetite regulation at the level that incretin therapies now achieve.

How GLP-1 Receptor Agonists Work Differently

GLP-1 receptor agonists mimic the incretin hormone glucagon-like peptide-1, which the gut releases after eating. These drugs bind to GLP-1 receptors in the hypothalamus, brainstem, and gastrointestinal tract to reduce appetite, slow gastric emptying, and improve insulin sensitivity. The mechanism is fundamentally different from older approaches that relied on stimulant effects, fat malabsorption, or single-neurotransmitter modulation.

Central Appetite Suppression

Native GLP-1 has a half-life of about two minutes. Semaglutide's structural modifications (an albumin-binding fatty acid chain and amino acid substitutions) extend its half-life to approximately seven days, allowing once-weekly dosing. The drug crosses the blood-brain barrier and acts directly on hypothalamic neurons involved in energy homeostasis. This produces a sensation of fullness that patients describe as "food noise" disappearing, not the jittery appetite suppression of stimulant-based drugs.

Dual and Triple Incretin Targeting

Tirzepatide goes further. It activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity states: "Tirzepatide, a dual GIP and GLP-1 receptor agonist, has demonstrated the greatest weight reduction among currently approved anti-obesity medications". Retatrutide, a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed 24.2% mean weight loss at 48 weeks in a phase 2 trial (N=338) and is currently in phase 3 development.

Gastric Emptying and Gut Signaling

GLP-1 RAs slow gastric emptying by 20 to 40%, which prolongs post-meal satiety and reduces caloric intake independently of central appetite effects. Older drugs did not have this dual central-peripheral mechanism. Phentermine works almost exclusively through central norepinephrine release, while orlistat has no appetite-modifying properties at all.

Clinical Trial Evidence: Magnitude of Weight Loss

The weight loss produced by GLP-1 RAs in randomized controlled trials dwarfs what older agents achieved. The difference is not incremental. It represents a categorical shift.

STEP Trials (Semaglutide 2.4 mg)

In STEP-1 (N=1,961), adults without diabetes receiving semaglutide 2.4 mg lost 14.9% of body weight at 68 weeks versus 2.4% with placebo. STEP-2 enrolled adults with type 2 diabetes and showed 9.6% weight loss. STEP-3 combined semaglutide with intensive behavioral therapy and reached 16.0% loss. More than one-third of STEP-1 participants lost 20% or more of their body weight.

Compare this to the best results from older agents: phentermine-topiramate ER (Qsymia) in the EQUIP trial produced 10.9% weight loss at the highest dose (15/92 mg), making it the most effective pre-GLP-1 medication, but with more neuropsychiatric and teratogenic concerns.

SURMOUNT Trials (Tirzepatide)

SURMOUNT-1 (N=2,539) showed tirzepatide at the 15 mg dose produced 22.5% mean weight loss at 72 weeks. Over half of participants in the highest dose group lost 20% or more. SURMOUNT-2, in adults with type 2 diabetes, demonstrated 14.7% loss at the top dose. These results approach what bariatric surgery delivers (typically 25 to 30% total body weight loss with sleeve gastrectomy).

Head-to-Head Data

No large randomized trial has directly compared semaglutide 2.4 mg to phentermine or orlistat. However, network meta-analyses consistently rank GLP-1 RAs and dual agonists above all other pharmacotherapies. A 2024 meta-analysis in JAMA examining 141 trials found that tirzepatide 15 mg ranked first for percentage weight loss among all approved and investigational anti-obesity medications, followed by semaglutide 2.4 mg.

Cardiovascular and Metabolic Benefits Beyond Weight

Older anti-obesity drugs were approved strictly based on weight outcomes. GLP-1 RAs have demonstrated benefits across cardiovascular, hepatic, renal, and glycemic endpoints that no prior weight-loss medication achieved.

The SELECT Trial

The SELECT trial (N=17,604) randomized adults with overweight or obesity and established cardiovascular disease (without diabetes) to semaglutide 2.4 mg or placebo. Semaglutide reduced major adverse cardiovascular events (MACE) by 20% over a median follow-up of 39.8 months. This was the first anti-obesity medication to demonstrate cardiovascular risk reduction.

The American Heart Association's 2024 presidential advisory noted: "These findings provide evidence that intentional weight loss with pharmacotherapy can reduce cardiovascular events in patients with overweight and obesity".

Metabolic Improvements

GLP-1 RAs improve HbA1c by 1.0 to 1.8 percentage points, reduce systolic blood pressure by 4 to 6 mmHg, lower triglycerides by 12 to 25%, and decrease waist circumference beyond what weight loss alone predicts. Tirzepatide in SURMOUNT-1 reduced C-reactive protein by 37% and improved multiple markers of cardiometabolic risk.

Orlistat modestly improves LDL cholesterol through reduced fat absorption, and naltrexone-bupropion has small effects on HbA1c, but neither has shown hard cardiovascular event reduction.

Safety Profile Comparison

The side-effect profiles of GLP-1 RAs and older anti-obesity drugs differ in both type and severity.

GLP-1 RA Side Effects

The most common adverse events with semaglutide and tirzepatide are gastrointestinal: nausea (40 to 44% in trials), vomiting, diarrhea, and constipation. These effects are dose-dependent and typically diminish during the titration period. In STEP-1, the discontinuation rate due to adverse events was 7.0% for semaglutide versus 3.1% for placebo.

Rare but serious concerns include pancreatitis (incidence approximately 0.1 to 0.3%), gallbladder disease (reported in 2.6% of semaglutide-treated patients in STEP trials), and a signal for thyroid C-cell tumors observed in rodent studies. The FDA label carries a boxed warning for medullary thyroid carcinoma risk in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2.

Older Drug Side Effects

Phentermine raises heart rate and blood pressure, can cause insomnia and anxiety, and carries abuse potential as a sympathomimetic. Orlistat causes steatorrhea, fecal incontinence, and fat-soluble vitamin malabsorption. Naltrexone-bupropion carries a boxed warning for suicidal thoughts and behavior. Lorcaserin was voluntarily withdrawn after a post-marketing safety trial showed a numerical increase in cancer diagnoses (7.7% vs. 7.1% with placebo over five years).

Tolerability in Practice

The GI effects of GLP-1 RAs, while common, are generally manageable with slow dose titration over 16 to 20 weeks. Older drugs had side effects that were harder to mitigate: there is no practical way to reduce orlistat's GI effects other than restricting dietary fat, and phentermine's cardiovascular stimulation limits its use in patients with hypertension or heart disease.

Duration of Treatment and Weight Regain

A defining difference between GLP-1 RAs and older medications is the intended duration of therapy and the consequences of stopping.

Chronic Treatment Model

GLP-1 RAs are approved for chronic, indefinite use. The STEP-4 withdrawal trial demonstrated that after 20 weeks of semaglutide-induced weight loss, participants who switched to placebo regained two-thirds of their lost weight over the following 48 weeks. This confirmed obesity as a chronic disease requiring ongoing treatment, similar to hypertension or type 2 diabetes.

Short-Term Approach of Older Drugs

Phentermine's FDA labeling restricts use to "a few weeks," reflecting a time when obesity treatment was viewed as a short-term intervention. Patients lost modest weight, stopped the drug, and regained it. This cycle reinforced the misconception that medication-based weight loss was inherently temporary. Orlistat and naltrexone-bupropion are approved for longer use, but real-world adherence at 12 months is low (under 30% in pharmacy claims data).

GLP-1 RAs have shifted clinical practice toward viewing anti-obesity pharmacotherapy as maintenance treatment. The weight regain observed in STEP-4 mirrors what happens when a patient stops antihypertensive medication: blood pressure returns. The biology is the same.

Cost and Access: The Practical Divide

GLP-1 RAs offer greater efficacy but at significantly higher cost than older alternatives.

Pricing Gap

Branded semaglutide (Wegovy) lists at approximately $1,349 per month. Tirzepatide (Zepbound) lists at approximately $1,060 per month. By comparison, generic phentermine costs $15 to 40 per month, generic orlistat (Alli OTC) runs $40 to 60 per month, and naltrexone-bupropion (Contrave) costs around $200 to 300 per month without insurance.

Insurance Coverage

Medicare Part D is statutorily excluded from covering anti-obesity medications, though legislative efforts (the Treat and Reduce Obesity Act) have been reintroduced repeatedly. Commercial insurers increasingly cover GLP-1 RAs, but prior authorization requirements are common and often require documented failure of lifestyle intervention.

Compounded and Generic Pathways

The FDA has permitted compounded semaglutide during the branded product's shortage period, though regulatory status changes frequently. Generic versions of older drugs remain widely available and affordable, which keeps them relevant as first-line or adjunctive options for patients who cannot access or afford GLP-1 RAs.

Who Might Still Benefit from Older Medications

GLP-1 RAs are not universally appropriate. Older agents still have a role.

Clinical Scenarios Favoring Older Drugs

Phentermine-topiramate may be preferred in patients with comorbid migraine (topiramate has a migraine indication). Naltrexone-bupropion can be useful in patients with obesity and depression or tobacco dependence, since bupropion treats both conditions. Orlistat may suit patients who specifically want a non-systemic option with no CNS effects.

Combination Approaches

Some clinicians combine phentermine with a GLP-1 RA during the titration period to provide appetite suppression while the incretin drug is being up-titrated. The 2024 Endocrine Society guideline acknowledges combination pharmacotherapy as reasonable when monotherapy produces insufficient weight loss, though large randomized trials of these specific combinations are lacking.

Patients who experience a weight-loss plateau on a GLP-1 RA at maximum dose may benefit from adding a complementary agent, though the evidence base for this strategy remains observational.

What Comes Next in Obesity Pharmacotherapy

The GLP-1 RA class continues to expand. Oral semaglutide 50 mg produced 15.1% weight loss in the OASIS-1 trial (N=667), eliminating the injection requirement. Survodutide, a dual GLP-1/glucagon agonist, showed 18.7% weight loss in a phase 2 study. Amycretin, an oral co-agonist of GLP-1 and amylin receptors, demonstrated 13% weight loss at 12 weeks in early-phase data from Novo Nordisk.

The trajectory is clear: each generation of incretin-based therapy widens the gap between new and old approaches. Older anti-obesity drugs served as the only available tools for decades, and they remain accessible options. But for most patients meeting criteria for pharmacotherapy, GLP-1 RAs and dual agonists now represent the standard of care.

Average weight loss with the best available GLP-1 RA (tirzepatide 15 mg) is 22.5% at 72 weeks, roughly four to seven times the efficacy of pre-incretin medications.